FDA reportedly looking for suppliers to ease methotrexate shortage

The US Food and Drug Administration is reportedly seeking temporary suppliers to help ease US shortages of methotrexate, a drug that is commonly used to treat cancer and autoimmune disorders such as rheumatoid arthritis.

An FDA spokesperson told Reuters that the agency was looking at "temporary importation options" for the drug. Current suppliers of the drug include Teva Pharmaceutical (NYSE:TEVA) and Pfizer (NYSE:PFE).

Last week, the FDA said that it was seeking out temporary suppliers for two key chemotherapy drugs, cisplatin and carboplatin. The agency recently authorized China's Qilu Pharmaceutical as a US supplier for cisplatin, according to Reuters.

More on Teva:

Teva, Walgreens, CVS, AbbVie to pay $17.3B in national opioid settlement

Teva Pharmaceutical settles opioid litigation with all 50 states

Teva Pharmaceutical S&P rating outlook changed to stable from positive